Metabolic Diseases  >>  emapticap pegol (NOX E36)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
emapticap pegol (NOX E36) / TME Pharma
NCT01547897 / 2011-005710-11: NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria

Checkmark P2a data: KIDNEY WEEK 2014
Oct 2014 - Oct 2014: P2a data: KIDNEY WEEK 2014
Checkmark
Jun 2014 - Jun 2014: 
Checkmark For diabetic nephropathy in patients with type 2 diabetes and albuminuria
More
Completed
2a
76
Europe
NOX-E36
TME Pharma AG
Type 2 Diabetes Mellitus, Albuminuria
09/13
12/13
NCT01085292: NOX-E36 Multiple Ascending Dose Study in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus

Completed
1/2
47
Europe
NOX-E36
TME Pharma AG, Profil Institut für Stoffwechselforschung GmbH
Type 2 Diabetes Mellitus
02/12
02/12

Download Options